Covered recipient · General Payments record
SHAKER R DAKHIL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$105,533.44
397 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,650.00 | 16 |
| Charitable Contribution | $30,000.00 | 1 |
| Consulting Fee | $18,081.54 | 7 |
| Food and Beverage | $7,987.86 | 338 |
| Travel and Lodging | $7,764.05 | 29 |
| Honoraria | $4,000.00 | 1 |
| Education | $49.99 | 5 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SHAKER R DAKHIL
NPI 1417918079 · CMS profile ID 199929
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
WICHITA, KS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 8; records 251–300 of 397 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
397 matching records · $105,533.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 397.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.33 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651319195 | CMS |
| Merck Sharp & Dohme Corporation | $14.30 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695463877 | CMS |
| Seattle Genetics, Inc. | $10.00 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678801111 | CMS |
| AbbVie, Inc. | $10.72 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647868081 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.97 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685753585 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4.04 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651319191 | CMS |
| PFIZER INC. | $10.81 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673118467 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.92 | 05/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651319193 | CMS |
| PFIZER INC. | $14.23 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119909 | CMS |
| Merck Sharp & Dohme Corporation | $17.85 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695458527 | CMS |
| Astellas Pharma US Inc | $125.00 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655527185 | CMS |
| Seattle Genetics, Inc. | $14.65 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678801105 | CMS |
| Astellas Pharma Global Development | $276.87 | 04/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641929915 | CMS |
| Astellas Pharma Global Development | $993.40 | 04/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641929917 | CMS |
| Astellas Pharma Global Development | $82.17 | 04/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641929919 | CMS |
| Novartis Pharmaceuticals Corporation | $3.60 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659154017 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.25 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628451129 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.70 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651319189 | CMS |
| Seattle Genetics, Inc. | $14.47 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678801107 | CMS |
| Lilly USA, LLC | $26.04 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658152175 | CMS |
| Novartis Pharmaceuticals Corporation | $15.22 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659154027 | CMS |
| Genentech USA, Inc. | $6.36 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681319051 | CMS |
| Rigel Pharmaceuticals, Inc. | $16.54 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698994129 | CMS |
| PFIZER INC. | $12.26 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673119531 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.86 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685046589 | CMS |
| Array BioPharma Inc. | $24.41 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700973167 | CMS |
| EISAI INC. | $3,125.00 | 04/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697036463 | CMS |
| Taiho Oncology, Inc. | $11.56 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679412363 | CMS |
| Celgene Corporation | $124.97 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672847083 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.53 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651319185 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.15 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651319187 | CMS |
| Novartis Pharmaceuticals Corporation | $14.84 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659153973 | CMS |
| AMAG Pharmaceuticals, Inc. | $10.46 | 04/12/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698512359 | CMS |
| Janssen Biotech, Inc. | $8.10 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658388593 | CMS |
| Merck Sharp & Dohme Corporation | $15.45 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695425087 | CMS |
| Incyte Corporation | $9.30 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666245083 | CMS |
| EISAI INC. | $19.23 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697004513 | CMS |
| Amgen Inc. | $15.07 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663035783 | CMS |
| Merck Sharp & Dohme Corporation | $16.42 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695433697 | CMS |
| Taiho Oncology, Inc. | $10.78 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679412359 | CMS |
| Verastem, Inc. | $125.00 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699792481 | CMS |
| AbbVie, Inc. | $8.19 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647868067 | CMS |
| Genentech USA, Inc. | $12.35 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681311547 | CMS |
| Heron Therapeutics, Inc. | $13.14 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674510327 | CMS |
| TerSera Therapeutics LLC | $33.18 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699766085 | CMS |
| TESARO, Inc. | $13.32 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675557805 | CMS |
| Merck Sharp & Dohme Corporation | $18.09 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695392933 | CMS |
| PFIZER INC. | $5.09 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673133137 | CMS |
| TerSera Therapeutics LLC | $33.18 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699766083 | CMS |
| PFIZER INC. | $6.00 | 03/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673128715 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $469.66 | 2 |
| PY2025 | Principal investigator | $1,587,717.72 | 52 |
| PY2024 | Principal investigator | $1,520,759.10 | 52 |
| PY2023 | Principal investigator | $633,759.48 | 103 |
| PY2022 | Principal investigator | $664,292.24 | 79 |
| PY2021 | Principal investigator | $1,279,119.78 | 115 |
| PY2020 | Recipient | $898.50 | 2 |
| PY2020 | Principal investigator | $2,529,101.57 | 167 |
| PY2019 | Recipient | $79,430.00 | 5 |
| PY2019 | Principal investigator | $2,445,340.11 | 126 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
54 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,222.39 | 12/31/2025 | Non-covered Recipient Entity Cancer Center of Kansas | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 | No dispute reported | 06/30/2026 | 1232927907 |
| Principal investigator 1 | Amgen Inc. | $3,500.00 | 12/23/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) | No dispute reported | 06/30/2026 | 1246639891 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,639.00 | 12/23/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190332177 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,025.00 | 12/09/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190332179 |
| Recipient | Novartis Pharmaceuticals Corporation | $332.54 | 12/07/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291284 |
| Principal investigator 1 | Amgen Inc. | $38,476.00 | 11/25/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) | No dispute reported | 06/30/2026 | 1246649890 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,282.00 | 11/12/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190332283 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,395.56 | 11/11/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190298334 |
| Principal investigator 1 | Incyte Corporation | $23,619.09 | 11/10/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240512131 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $214.02 | 10/28/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190298325 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $151,514.98 | 10/27/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190298311 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $411.00 | 10/23/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS P.A. | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737859 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $248.00 | 10/23/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS P.A. | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737861 |
| Principal investigator 1 | Amgen Inc. | $95,594.72 | 09/24/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS, HERITAGE PLAZA MEDICAL BUILDING | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) | No dispute reported | 06/30/2026 | 1246639889 |
| Principal investigator 1 | PFIZER INC. | $1,519.00 | 09/02/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228757713 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,806.00 | 08/26/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190332279 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,025.00 | 08/12/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190332175 |
| Recipient | Novartis Pharmaceuticals Corporation | $137.12 | 08/05/2025 | Covered Recipient Physician | CABL001AUS08 | No dispute reported | 06/30/2026 | 1190293488 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,769.00 | 07/22/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190332281 |
| Principal investigator 1 | Incyte Corporation | $22.05 | 06/24/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240512118 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $967.40 | 06/13/2025 | Non-covered Recipient Entity Cancer Center Of Kansas | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies | No dispute reported | 06/30/2026 | 1235998430 |
| Principal investigator 1 | Genentech, Inc. | $1,750.05 | 06/09/2025 | Non-covered Recipient Entity MAYO CLINIC ROCHESTER REMIT PROCESSING | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211622922 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,515.48 | 06/05/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS PA | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184204155 |
| Principal investigator 1 | BeiGene, Ltd. | $2,499.00 | 05/20/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322622 |
| Principal investigator 1 | BeiGene, Ltd. | $3,399.00 | 05/12/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325110 |
| Principal investigator 1 | PFIZER INC. | $1,519.00 | 05/05/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228772190 |
| Principal investigator 1 | BeiGene, Ltd. | $1,552.00 | 04/29/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325112 |
| Principal investigator 1 | BeiGene, Ltd. | $2,025.00 | 04/29/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325114 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $4,560.72 | 04/28/2025 | Non-covered Recipient Entity Cancer Center Of Kansas | A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther | No dispute reported | 06/30/2026 | 1236531209 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $13,490.40 | 04/16/2025 | Non-covered Recipient Entity Cancer Center of Kansas | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 | No dispute reported | 06/30/2026 | 1232927905 |
| Principal investigator 1 | Incyte Corporation | $3,889.06 | 04/15/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240512123 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $16,515.50 | 04/10/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS PA | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | No dispute reported | 06/30/2026 | 1211583211 |
| Principal investigator 1 | BeiGene, Ltd. | $1,716.00 | 04/08/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322620 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,341.43 | 04/02/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS, PA | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543638 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $355,996.06 | 04/02/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190298330 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,921.00 | 03/27/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | Two arm Randomized Phase 3 study in high risk NSCLC comparing canakinumab vs placebo in Adjuvant Setting | No dispute reported | 06/30/2026 | 1190298319 |
| Principal investigator 1 | BeiGene, Ltd. | $4,214.00 | 03/25/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322618 |
| Principal investigator 1 | Acerta Pharma LLC | $848.20 | 03/19/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS, PA | a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia | No dispute reported | 06/30/2026 | 1185543634 |
| Principal investigator 1 | Acerta Pharma LLC | $4,609.09 | 03/13/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS, PA | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185543632 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $13,395.60 | 03/13/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS PA | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | No dispute reported | 06/30/2026 | 1211583208 |
| Principal investigator 1 | ABBVIE INC. | $13,000.00 | 03/07/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS P A | M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202461402 |
| Principal investigator 1 | BeiGene, Ltd. | $1,918.00 | 02/25/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322616 |
| Principal investigator 1 | PFIZER INC. | $1,519.00 | 02/24/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228787799 |
| Principal investigator 1 | BeiGene, Ltd. | $13,038.00 | 02/11/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322786 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,916.00 | 02/11/2025 | Non-covered Recipient Entity Translational Oncology Research International | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER | No dispute reported | 06/30/2026 | 1235992897 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 02/03/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325314 |
| Principal investigator 1 | Incyte Corporation | $44.10 | 01/30/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240512113 |
| Principal investigator 1 | BeiGene, Ltd. | $2,025.00 | 01/28/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320282 |
| Principal investigator 1 | BeiGene, Ltd. | $4,414.00 | 01/28/2025 | Non-covered Recipient Entity Cancer Center of Kansas, P.A. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320284 |
| Principal investigator 1 | Acerta Pharma LLC | $5,331.00 | 01/23/2025 | Non-covered Recipient Entity TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL | A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation | No dispute reported | 06/30/2026 | 1185543636 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $21,185.00 | 01/15/2025 | Non-covered Recipient Entity Cancer Center Of Kansas | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236531205 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $41,809.56 | 01/09/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190298339 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 01/08/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211673720 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $686,071.45 | 01/01/2025 | Non-covered Recipient Entity CANCER CENTER OF KANSAS | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190298316 |